Metastatic and triple-negative breast cancer: challenges and treatment options

Al-Mahmood, Sumayah, Sapiezynski, Justin, Garbuzenko, Olga B., Minko, Tamara·2018·Drug Delivery and Translational Research
DOI 10.1007/s13346-018-0551-3

Cites (269)

Items 201–269 of 269

  1. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies
    Joyce O’Shaughnessy, Kristi J. McIntyre, Lee Steven Schwartzberg · 2015 · SpringerPlus
  2. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer – A phase II study
    Hanan Shawky, Hesham Ahmed Tawfik · 2014 · Journal of the Egyptian National Cancer Institute
  3. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting
    George Dranitsaris, Nancy L. Beegle, Traci L. Kalberer · 2014 · Journal of Oncology Pharmacy Practice
  4. Significance of the tumor protease cathepsin D for the biology of breast cancer.
    Darius Dian, Sabine Heublein, Irmi Wiest · 2014 · PubMed
  5. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
    John Paul Crown, Megan Kennedy, Patricia Tresca et al. · 2013 · Annals of Oncology
  6. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer
    Alessandra Fabi, Roberta Merola, Gianluigi Ferretti, Anna Di Benedetto, Barbara Antoniani, Cristiana Ercolani, Cecilia Nisticò, Paola Papaldo, Mariangela Ciccarese, Isabella Sperduti et al. · 2013 · Expert Opinion on Pharmacotherapy
  7. Expression of cathepsin-D in primary breast cancer and corresponding local recurrence or metastasis: an immunohistochemical study.
    Darius Dian, Thomas Vrekoussis, N Shabani · 2012 · PubMed
  8. Trastuzumab in advanced breast cancer – a decade of experience in Germany
    Christian Jackisch, Winfried Schoenegg, Dietmar Arno Reichert · 2014 · BMC Cancer
  9. Prospective Study of Vinorelbine and Capecitabine Combination Therapy in Chinese Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
    Ying Fan, Binghe Xu, Peng Yuan · 2010 · Chemotherapy
  10. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer
    Niki Karachaliou, N. Ziras, Konstantinos N. Syrigos · 2012 · Cancer Chemotherapy and Pharmacology
  11. Interaction between p53 Mutation and a Somatic HDMX Biomarker Better Defines Metastatic Potential in Breast Cancer
    Anna M. Grawenda, Elen K. Møller, Suzanne Lam, Emmanouela Repapi, Amina F.A.S. Teunisse, Grethe I.G. Alnæs, Anne‐Lise Børresen‐Dale, Vessela Nedelcheva Kristensen, Colin R. Goding, Aart G. Jochemsen et al. · 2015 · Cancer Research
  12. Criteria for prediction of metastatic axillary lymph nodes in early-stage breast cancer
    Hélio Rubens de Oliveira Filho, Maíra Teixeira Dória, José Roberto Morales Piato · 2015 · Revista Brasileira Ginecologia e Obstetrícia
  13. Gemcitabine and Trastuzumab Combinations for Patients with Metastatic Breast Cancer Overexpressing HER2/neu
    Steven Stein, Angie DeMichele, Susan M. Domchek · 2004 · Clinical Breast Cancer
  14. Vandetanib as a potential treatment for breast cancer
    Antonella De Luca, Amelia D’Alessio, Monica Rosaria Maiello · 2014 · Expert Opinion on Investigational Drugs
  15. Differences in breast cancer biological characteristics between ethnic groups in New Zealand
    Michelle Weston, David P. Moss, JOANNA M. STEWART · 2007 · Breast Cancer Research and Treatment
  16. Effect of Lymphangiogenesis and Lymphovascular Invasion on the Survival Pattern of Breast Cancer Patients
    Pradyumna Kumar Sahoo, Debarshi Jana, Palash Kumar Mandal · 2014 · Asian Pacific Journal of Cancer Prevention
  17. Multifunctional Nanotherapeutics for Cancer
    Tamara Minko, Jayant J. Khandare, Alexandre A. Vetcher, В А Солдатенков, Olga B. Garbuzenko, Maha Saad, Vitaly P. Pozharov · 2008 · Fundamental biomedical technologies
  18. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer
    Shaheenah S. Dawood, Bhawna Sirohi · 2015 · Future Oncology
  19. Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy
    Chuanli Ren, Chongxu Han, Deyuan Fu, Daxin Wang, Hui Chen, Yong Chen, Ming Shen · 2015 · International Journal of Cancer
  20. Vascular Invasion in Triple-Negative Carcinoma of the Breast Identified by Endothelial Lymphatic and Blood Vessel Markers
    Hajime Kuroda, Maki Nakai, Kiyoshi Ohnisi, Takafumi Ishida, Mina Kuroda, Shinji Itoyama · 2010 · International Journal of Surgical Pathology
  21. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer
    Jung Yong Hong, Yeon Hee Park, Moon Ki Choi · 2015 · Clinical Breast Cancer
  22. Gemcitabine and taxanes in metastatic breast cancer
    Dino Amadori, Lorenzo Cecconetto · 2006 · Annals of Oncology
  23. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer
    Emmanouil Kontopodis, Nikolaos K. Kentepozidis, Ch. Christophyllakis et al. · 2014 · Cancer Chemotherapy and Pharmacology
  24. Long-term complete remission of metastatic breast cancer induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor
    Go Wakabayashi · 2014 · American Journal of Case Reports
  25. Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study
    Christina Addison, Gregory R. Pond, Brandy Cochrane · 2015 · Journal of bone oncology
  26. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
    Ji Soo Park, Hei‐Cheul Jeung, Sun Young Rha et al. · 2014 · Cancer Chemotherapy and Pharmacology
  27. Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer
    K. C. Patel, Kelly Hageman, Maryann R. Cooper · 2014 · American Journal of Health-System Pharmacy
  28. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
    Jian Zhang, Shiyang Gu, Yu Gan · 2012 · Cancer Chemotherapy and Pharmacology
  29. Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
    Yvonne Hui-Fang Teng, Aye‐Aye Thike, Nan-Soon Wong · 2011 · Recent Patents on Anti-Cancer Drug Discovery
  30. Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model
    Young‐Jin Choi, Seok Jin Nam, Myung Jin Son, Dae-Kyeum Kim, Jeong Han Kim, Jung‐Hyun Yang, Mi‐Hyun Kim, Hyun Song, Do‐Hyun Nam, Sa Ik Bang · 2006 · Oncology Reports
  31. Receptor Mediated Delivery Systems for Cancer Therapeutics
    Tamara Minko · 2011 · Springer eBooks
  32. Tumeurs secondaires : incidence, facteurs de risque et recommandations de prévention
    Charlotte Demoor-Goldschmidt, Chiraz Fayech, Pauline Girard · 2015 · Bulletin du Cancer
  33. Increased oxidative damage to membrane lipids following surgery for breast cancer.
    Paweł Szychta, Marek Zadrożny, Andrzej Lewiñski · 2014 · PubMed
  34. Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004.
    H. Terunuma · 2012 · PubMed
  35. A Phase I Study of Capecitabine, Oxaliplatin, and Lapatinib in Metastatic or Advanced Solid Tumors
    Trevor W. Dennie, Ronald Alan Fleming, Carolyn J. Bowen · 2011 · Clinical Colorectal Cancer
  36. Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients
    Teresa Gamucci, Luca I. Moscetti, Lucia Mentuccia · 2013 · Journal of Cancer Research and Clinical Oncology
  37. Proliferating cell nuclear antigen labeling index and p53 expression predict outcome for breast cancer patients with four or more lymph node metastases
    Tsutomu Takashima, Naoyoshi Onoda, Tetsuro Ishikawa · 2001 · International Journal of Molecular Medicine
  38. Relation of Pre-anthracycline Serum Bilirubin Levels to Left Ventricular Ejection Fraction After Chemotherapy
    Trinity Vera, Ralph B. D’Agostino, Jennifer H. Jordan · 2015 · The American Journal of Cardiology
  39. The tumor-to-breast volume ratio (TBR) predicts cancer-specific survival in breast cancer patients who underwent modified radical mastectomy
    Jiahuai Wen, Feng Ye, Xiaojia Huang · 2015 · Tumor Biology
  40. Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure
    Kazuhiro Araki, Naoko Ishida, Rie Horii, Shunji Takahashi, Futoshi Akiyama, Yoshinori Ito, Shinji Ohno · 2015 · Expert Opinion on Pharmacotherapy
  41. Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy
    Yanin Chávarri-Guerra, Michaela Jane Higgins, Jackie D. Szymonifka et al. · 2014 · British Journal of Cancer
  42. The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration
    Mehmet Alı Nahıt Şendur, Sercan Aksoy, Nuriye Özdemir, Ozan Yazıcı, Nurullah Zengin, Kadri Altundağ · 2014 · Current Medical Research and Opinion
  43. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer
    Marissa Michelle Howard-McNatt, Julia A. Lawrence, Susan Anitra Melin · 2013 · The American Journal of Surgery
  44. ecancermedicalscience
    Efrén Bolívar Abreu, Pedro Martinez, Luís Betancourt · 2016 · ecancermedicalscience
  45. Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
    Jung Sun Kim, In Hae Park, Keun Seok Lee · 2014 · Journal of Breast Cancer
  46. Breast cancer metastasis burden in sentinel nodes analysed using one-step nucleic acid amplification predicts axillary nodal status
    Thomas Daniel Milner, Simon de Lusignan, Simon Jones · 2015 · The Breast
  47. DNA ploidy and TLI in association with other prognostic parameters in breast cancer.
    Cecilia Midulla, M Cenci, De Iorio P · 1999 · PubMed
  48. Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer.
    Antonio Antón, Ana M. Lluch, Antonio Casado · 2010 · PubMed
  49. Expression of human mammaglobin as a marker of bone marrow micrometastasis in breast cancer
    Yunjiang Liu, Li Ma, Xianyi Liu · 2011 · Experimental and Therapeutic Medicine
  50. Progestin as an alternative treatment option for multi-treated recurrent triple-negative breast cancer
    Xiang-ying Meng, Song Wu, Zefei Jiang, Bing Sun, Yuzhen Ma, Xin Zhao, Lijuan Ding, Yue Wang, Tao Wang, Shaohua Zhang et al. · 2013 · Swiss Medical Weekly
  51. Risk Factors for the Development of Uterine Cancer in Breast Cancer Survivors: An Army of Women Study
    Diogo Torres, John Allen Myers, Leah Eshraghi · 2014 · Annals of Surgical Oncology
  52. A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer
    Kimihiro Tanaka, Eriko Tokunaga, Nami Yamashita, Kenji Taketani, Sayuri Akiyoshi, Masaru Morita, Yoshihiko Maehara · 2013 · Surgery Today
  53. Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation
    Esin Oktay, Özlem Yersal, Nezih Meydan · 2013 · Case Reports in Oncological Medicine
  54. Axillary treatment for patients with early breast cancer and lymph node metastasis: systematic review protocol
    Amit Goyal, Lelia Duley, Apostolos Fakis · 2013 · World Journal of Surgical Oncology
  55. Illuminating anthracycline cardiotoxicity: the renaissance of evidence-based onco-cardiology.
    Isaac B. Rhea, Guilherme H. Oliveira · 2015 · PubMed
  56. [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
    Hongyan Huang, Zefei Jiang, Tao Wang · 2011 · PubMed
  57. [A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].
    Yoshifumi Fujita, Naruhiko Mizuta, Koichi Sakaguchi et al. · 2012 · PubMed
  58. [A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].
    Masayuki Shibasaki, Asami Tanabe, Tateo Toda · 2015 · PubMed
  59. Immunohistochemical Study of Apoptotic Marker p53 as a Prognostic Factor in Breast Cancer
    К. С. Лоскутова, M.P. Kirillina, Elena L. Lushnikova · 2014 · Bulletin of Experimental Biology and Medicine
  60. The Safety of Concentrated Trastuzumab in 100 ml of Saline Solution for Administration to Patients with HER2-Positive Breast Cancer: A Phase 1 Study
    Norihiko Sengoku, Hirokazu Tanino, Yoshimasa Kosaka, Mariko Kikuchi, Hiroshi Nishimiya, Mina Waraya, Hiroshi Katoh, Takumo Enomoto, Takeo Sato, Masaru Kuranami et al. · 2014 · Chemotherapy
  61. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis
    Virginie Nerich, J. Chelly, Philippe Montcuquet et al. · 2013 · Journal of Oncology Pharmacy Practice
  62. Origin of cells cultured in vitro from human breast carcinomas traced by cyclin D1 and HER2/neu FISH signal numbers.
    Eva Matoušková, Iva Kudlackova, A Chaloupková · 2005 · PubMed
  63. Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.
    Kazuo Ishizuna, Jun Ninomiya, Toshihisa Ogawa · 2014 · PubMed
  64. [Breast cancer risk factors--possibilities of primary prevention].
    Maria Jokiel, Magdalena Bielska‐Lasota · 2010 · PubMed
  65. [The place of surgery in the treatment of advanced localized, recurrent and metastatic breast cancer].
    Maurice Matter, Michael E. Dusmet, F Chevalley · 2000 · PubMed
  66. [A case of recurrent breast cancer responding to vinorelbine/trastuzumab combination therapy].
    Minoru Fujisawa, Toshitaka Uomori, Kazuhiro Takehara et al. · 2009 · PubMed
  67. [Analysis of prognostic parameters in patients with breast cancer of size smaller than or equal to 2 cm].
    Cheng Xue, Fangmeng Fu, Chuan Wang · 2015 · PubMed
  68. [Oral combination chemotherapy with capecitabine and cyclophosphamide in combination with endocrine therapy and anti-HER2 therapy for advanced and metastatic breast cancer].
    Ryuji Okamura, Tatsushi Kato, Ritsuko Sata · 2012 · PubMed
  69. [Clinical effect of Vinorelbine monotherapy in 18 cases of advanced or metastatic breast cancer].
    Shinsuke Sasada, Shoichiro Ohtani, Ryuji Kim · 2008 · PubMed